CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds
The contract research organization Syneos Health didn’t hold up its end of the deal and use “commercially reasonable efforts” when setting up a trial for a biotech client, an arbitration panel found. It also determined that the client owes the CRO about $1.7 million in damages — less than half of what Syneos was asking for in payment.
FSD Pharma, which contracted Syneos to set up a Phase II trial in 2021 for one of its drug candidates dubbed FSD 210, claimed in a statement Monday that Syneos failed to enroll the expected number of patients and hit enrollment deadlines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.